Gain Therapeutics, Inc. (GANX) — 10-Q Filings

10-Q Filings (5)

• Gain Therapeutics Narrows Loss, Cash Dwindles Amid R&D Cuts — Aug 12, 2025 Risk: high
  Gain Therapeutics, Inc. (GANX) reported a net loss of $10,339,145 for the six months ended June 30, 2025, an improvement from the $12,157,272 net loss in the sa
• Gain Therapeutics Q1 2025: Balance Sheet Insights — May 14, 2025 Risk: medium
  Gain Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company's financial statements show significant changes in its bala
• Gain Therapeutics Reports Q3 2024 Results — Nov 14, 2024 Risk: medium
  Gain Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported interest income and expense net of $25,962,246 for the nin
• Gain Therapeutics Files 10-Q with $25.17M Interest Income — Aug 8, 2024 Risk: medium
  Gain Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported interest income and expense net of $25,172,573 for the period.
• Gain Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk:
  Gain Therapeutics, Inc. (GANX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Gain Therapeutics, Inc. filed a 10-Q report for the period ending M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX